Celgene now owns a checkpoint inhibitor for solid tumors, but is Beigene deal too late for cancer immunotherapy race? – STAT
STAT |
Celgene now owns a checkpoint inhibitor for solid tumors, but is Beigene deal too late for cancer immunotherapy race?
STAT Celgene says securing ownership of a checkpoint inhibitor is important for its cancer immunotherapy plans for solid tumors. But the licensing deal also looks a bit desperate given the gap between itself and checkpoint inhibitor frontrunners like Merck … |
